Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 3/20 | 0.38 |
| ▸ | ARG1 | P05089 | 3/20 | 0.37 |
| ▸ | ARG2 | P78540 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27911982 | 0.80 | ARG1 (0.45) | ARG1ARG2POLBKCNH2OPRM1 | |
| SCHEMBL7327831 | 0.78 | PAOX (0.43) | ACLYACACBACACA | |
| Hydrochloric Acid SCHEMBL11725592 | 0.77 | ARG1 (0.46) | ARG1ARG2POLBKCNH2MEN1 | |
| Hydrochloric Acid SCHEMBL27945156 | 0.75 | SIGMAR1 (0.46) | POLBMEN1KMT2A | |
| SCHEMBL15434608 | 0.75 | SMN1; SMN2 (0.56) | ARG1ARG2MEN1KMT2AOPRM1 | |
| Hydrochloric Acid SCHEMBL27945162 | 0.75 | SIGMAR1 (0.46) | POLBMEN1KMT2A | |
| SCHEMBL20527341 | 0.72 | GLA (0.52) | POLBHTT | |
| SCHEMBL1515165 | 0.70 | HTR2B (0.34) | KCNA3 | |
| SCHEMBL18173152 | 0.69 | KDM4E (0.37) | — | |
| SCHEMBL12155298 | 0.69 | CACNA1I (0.48) | CACNA1IKCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | claimed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | claimed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | KCNA3 2746/4885ARG1 180/4885ARG2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.